Sana Biotechnology, Inc. · NASDAQ:SANA
Sana Biotechnology — Investor Presentation (January 2023)
32 slides from Sana Biotechnology's investor presentation, Jan 10, 2023
Slide 1: Corporate Presentation January 2023
Corporate Presentation January 2023 Sana Biotechnology TM Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this presentation, including, among others, statements r
Slide 3: Engineered Cells as Medicines
Sana’s ambition is to repair or replace any cell in the body. Technologies address fundamental barriers: Hypoimmune (HIP) technology: Overcoming immune rejection of allogeneic cells Fusogen technology: In vivo delivery of genomic modification reagents in a cell-specific manner Overcoming immune reje
Slide 4: Pipeline poised to deliver multiple clinical data readouts over next several years
Pipeline poised to deliver multiple clinical data readouts over next several years Sana’s platforms, technology, and programs 1IST, investigator sponsored trial. Abbreviations: ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; HD, Huntington’s disease; IND, investigational new dr
Slide 5: Immune rejection remains the largest problem in transplant and cellular medicine
~75 years of organ and bone marrow transplants – immune rejection remains the largest problem Cell-based medicines face similar immune rejection challenges Significant immunosuppression is current standard Genome modification efforts to date have generally been incomplete Autologous therapies have l
Slide 6: Sana's hypoimmune solution: Leverage insights from nature
Sana’s hypoimmune solution: Leverage insights from nature Abbreviations: MHC, major histocompatibility complex; RBC, red blood cell. Current clinical platform with multiple ongoing approaches in research phase. Leverage insights from nature to create hypoimmune cells Sana’s hypoimmune approach Red b
Slide 7: HIP modifications offer superior protection from innate cell killing
Sana’s HIP modifications offer superior protection from innate cell killing Abbreviations: HLA, human leukocyte antigen; iPSC, induced pluripotent stem cells; KI, knock-in; KO, knock-out; NK, natural killer; PD-L1, Programmed death-ligand 1. No Killing Killing Killing Killing No Killing No Killing T
Slide 8: HIP modifications offer superior protection from innate cell killing
Sana’s HIP modifications offer superior protection from innate cell killing Abbreviations: HLA, human leukocyte antigen; iPSC, induced pluripotent stem cells; KI, knock-in; KO, knock-out; NK, natural killer; PD-L1, Programmed death-ligand 1. No Killing Killing Killing Killing No Killing No Killing T
Slide 9: Hypoimmune cells survive in vivo in NHP while unmodified iPSCs get rejected
Hypoimmune cells survive in vivo when transplanted in NHP while unmodified iPSCs get rejected Abbreviations: NHP, non-human primate; Txp, transplant; WT, wild type. A B NHP unmodified iPSCs (WT) & NHP hypoimmune iPSCs (HIP) were transplanted into eight allogeneic NHP recipients [BAR CHART] Sana Biot
Slide 10: Survival of allogeneic hypoimmune islet cells for 10+ months without immunosuppression
Survival of allogeneic hypoimmune pancreatic islet cells for 10+ months without immunosuppression Study design: NHP primary islet cells isolated and HIP-edited Cells injected intramuscularly into a healthy, allogeneic NHP without immunosuppression WT HIP Survival HIP results (follow up shown: 10 mon
Slide 11: Survival and immune evasion after transplant for different cell types in NHP studies
Survival and immune evasion after transplant for different cell types in multiple NHP studies Abbreviations: RPE, retinal pigment epithelium. HIP primary islets HIP iPSC-derived RPE HIP iPSC-derived cardiomyocytes HIP iPSC Sana Biotechnology TM © 2020-2023 Sana Biotechnology. All rights reserved. 11
Slide 12: Hematologic cancers continue to have a high unmet need
Challenges Autologous CAR T cell scalability Many patients fail CAR T treatment Allogeneic CAR T cells immune rejection limits persistence and efficacy Opportunity Known targets Known efficacy and safety bar Sana’s HIP CAR T platform can address challenges and exploit opportunities Hematologic cance
Slide 13: HIP platform can create a regenerative pipeline for allogeneic CAR T therapies
Sana’s HIP platform can create a regenerative pipeline for allogeneic CAR T therapies 1Based on current scale, assuming 50% hold back for analytical and other testing, and variability in dose in Phase 1 study. Abbreviations: Cas12b, CRISPR associated protein 12b; GPRC5D, G protein–coupled receptor,
Slide 14: SC291 tumor control compared to standard CD19 CAR T cells
SC291 tumor control comparable at early timepoints to standard CD19 CAR T cells SC291 tumor control superior at later timepoints to standard CD19 CAR T cells SC291 controls tumors when animals are rechallenged with tumor HIP CD19 CAR T cells demonstrate persistence and continued efficacy in humanize
Slide 15: SC291: Sana's CD19 HIP allogeneic CAR T
SC291: Sana’s CD19 HIP allogeneic CAR T IND filed First clinical data in 2023 Data show CAR T cell persistence correlates with long term complete response (CRs) rates1 Improved persistence can lead to best-in-class allogeneic CAR T platform Allogeneic HIP CAR T cell 1Porter et al. Science Translatio
Slide 16: SC262: Targeting patients with inadequate response to CD19 therapy
SC262: Targeting growing population of patients with inadequate response to CD19 therapy 1US, EU5, and Japan. 2Clarivate DRG NHL Market Forecast Nov 2021; 2027 Forecast is 2L+ LBCL patients. 3Di Blasi et al. Blood.2022; DESCAR-T registry. ~65% ~35% 100% ~12K ~12K Potential of ~7,800 CAR T failures a
Slide 17: SC262: Licensed CD22 CAR produced strong clinical data in CD19 failures
2021 ASH Miklos/Stanford SC262 Goals: File IND this year; clinical data in 2024 N=24 SC262: Licensed CD22 CAR produced strong clinical data in CD19 failures when part of autologous CAR T N=16 N=21 >50% 6-month CR rate in CD19 CAR failure DLBCL patients High rate of CRs in CD19 failure ALL patients ~
Slide 18: SC255: Licensed BCMA CAR produced strong clinical data in myeloma
SC255: Licensed BCMA CAR produced strong clinical data in myeloma when part of autologous CAR T 4 3 ORR: 98% 5 ORR: 95% ORR: 75% Total N=100 SC255 Goal: File IND as early as 2024 Prior CAR T n=12 No prior CAR T n=88 1 ~80% patients MRD negative at 12 months ~75% patients in CR/sCR with median follow
Slide 19: Goal is to build a best-in-class CAR T portfolio
Goal is to build a best-in-class CAR T portfolio to treat patients with a range of cancers and beyond 1Avezbakiyev et al. Blood. 2022 2Durie et al. The Oncologist. 2020 Abbreviations: SLE, systemic lupus erythematosus. Unlocking the potential of our allogeneic CAR T franchise across multiple patient
Slide 20: Type 1 diabetes represents a large unmet need
Disease caused by autoimmune destruction of insulin-producing beta cells in the pancreas; results in inability to control blood glucose Type 1 diabetes is a large unmet need with 1.6M patients in the U.S. and 2.4M in Europe2 Long-term complications: end-organ damage, including heart attack, stroke,
Slide 21: Hypoimmune islet cells for type 1 diabetes (SC451)
Sana’s solution: Hypoimmune islet cells for type 1 diabetes (SC451) PSCs can provide scale and product consistency HIP has potential to eliminate immunosuppression, protecting against both allogeneic and autoimmune rejection Islet cell transplantation has been shown to work in type 1 diabetes Islet
Slide 22: Proprietary type 1 diabetes model with humanized mice
D0 D3 D7 D5 D9 No glucose control Patient T cells eliminate islet cells due to autoimmunity Sana’s immunology, gene modification, & stem cell capabilities create proprietary type 1 diabetes model Abbreviations: T1DM, type 1 diabetes mellitus. Patient with T1DM PBMCs Autologous iPSC-derived islet cel
Slide 23: HIP iPSC-derived islet cells evade autoimmune killing and control glucose
HIP iPSC-derived pancreatic islet cells from T1DM patient evade autoimmune killing and control glucose Abbreviations: BLI, bioluminescence imaging. BLI: Islet Survival Glucose Control SC451 Goal: File IND and share clinical data in 2024 C-peptide [BAR_CHART] [BAR_CHART] [BAR_CHART] [BAR_CHART] Sana
Slide 24: Path to potential clinical validation of hypoimmune islet cells in 2023
Investigator sponsored trial Primary human HIP islet cells transplantation in type 1 diabetes patients Goal: Cell survival with no immunosuppression Goal: Data in 2023 Insight for SC451 Path to potential clinical validation of hypoimmune islet cells in T1DM patients in 2023 Cell survival & immune ev
Slide 25: Fusosome technology: cell-specific in vivo delivery platform
Fusosome technology: Development of cell-specific in vivo delivery platform Source: CDC website 3 2 1 Sana approach: Leverage insights from nature to deliver various payloads to specific cells Fusosome [BAR_CHART] [BAR_CHART] [BAR_CHART] Sana Biotechnology Tm© 2020-2023 Sana Biotechnology All rights
Slide 26: Fusogen technology could eliminate conditioning chemotherapy and ex vivo manufacturing
Fusogen technology has potential to eliminate conditioning chemotherapy and ex vivo manufacturing Current ex vivo approaches have limitations Fusogen platform offers potential to overcome these limitations [BAR_CHART] [BAR_CHART] Sana Biotechnology Tm© 2020-2023 Sana Biotechnology All rights reserve
Slide 27: T cell fusosome delivers CAR construct directly to T cells in vivo
T cell fusosome delivers CAR construct directly to T cells in vivo CAR activity Expression/recognition Amplification Target cell killing Target cell killing Specificity CD4/CD8 T cell transduction Expression Transgene integration and CAR expression Function Targeted cell killing T cell Fusosome Canc
Slide 28: IV fusosome CD19 CAR clears B cell tumors in humanized mice
IV administration of CD19 CAR delivered by fusosome can clear B cell tumors in humanized mice comparably to ex vivo CD19 CAR T CD19 CAR delivered by fusosome: in vivo CD19 CAR T: ex vivo Saline CD19 CAR T SG295 & Activated PBMC SG295 & Non-Activated PBMC Sana Biotechnology TM © 2020-2023 Sana Biotec
Slide 29: First clinical study incorporates SG295 made with V2.0 process
First clinical study incorporates SG295 made with V2.0 process Significant improvements in manufacturing process may lead to a better therapy Abbreviations: TU, transduction units. Potential for: Better efficacy Greater safety Higher yields and lower cost of goods SG295 made with V2.0 process result
Slide 30: Tumor control with fusosomes targeting other cell types and antigens
Tumor control achieved with fusosomes targeting other cell types and alternate tumor antigens CD4 T cell targeting fusosomes delivering CD19 CAR achieve tumor control in mice CD8 T cell targeting fusosomes delivering CD22 CAR achieve tumor control in mice D-4 D3 D6 D10 D24 D28 D14 D17 D21 Control Lo
Slide 31: Sana aspiration: Engineered cells as medicines
Sana aspiration: Engineered cells as medicines 1Does not incorporate hypoimmune genomic modifications Allogeneic CAR T Franchise Oncology: SC291, SC262, SC255 Autoimmune Stem Cell-Derived Type 1 Diabetes: SC451 CNS: SC3791 In vivo CAR T: SG295 Cell-specific in vivo HSC editing: SG418 Cell-specific d
Slide 32: Thank You
Thank You Sana Biotechnology www.sana.com Sana Biotechnology TM
Sana Biotechnology — Investor Presentation (January 2023) on 6ix